IMM 1.45% 34.0¢ immutep limited

one poster's well researched opinion, page-41

  1. 3,661 Posts.
    lightbulb Created with Sketch. 311
    ASX/Media Release (Code: PRR)
    14 September 2011
    CVacTM Phase III CANVAS Ovarian Cancer Clinical Update
    Highlights
    ? Upcoming CVac™ Phase III trial to be named CANVAS – CANcer VAccine Study
    ? Successful progress meeting recently completed with United States FDA
    ? German manufacturing authorisation for CVac™ commenced
    ? TGA manufacturing inspection completed in Melbourne
    ? CANVAS patient enrolment expected to commence Q4 this year

    Looks like a Phase III study to me boiler???
 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.